{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.4","upperLimit":"34.1","value":"12"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"114.3","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"Progression-Free Survival is defined as the interval of time between the date of the first dose of study drug and the earliest date of disease progression or death due to any cause. PFS was analyzed and listed for the ITT population. PFS was calculated using the Kaplan-Meier method.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Part 1 - Subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status\n\nPart 2: Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma","id":"OG000","title":"Part 1"},{"description":"Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma","id":"OG001","title":"Part 2"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The patients were assessed for PFS for up to 24 weeks","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}